FDA-Proposed Warning For OTC Bronchodilators “Alarming” – Wyeth
This article was originally published in The Tan Sheet
Executive Summary
FDA should re-word a cardiovascular warning statement it has proposed for OTC bronchodilator products because the statement is "unnecessarily alarming" and "goes beyond that which is supported by data," Wyeth Consumer Healthcare maintains
You may also be interested in...
FDA Final Rule For OTC Inhaler Labeling Requires Death Warning
FDA disagrees with industry comments regarding the health risks of using OTC asthma inhalers, rejecting suggested language for the final monograph covering asthma and bronchodilator drugs.
FDA Final Rule For OTC Inhaler Labeling Requires Death Warning
FDA disagrees with industry comments regarding the health risks of using OTC asthma inhalers, rejecting suggested language for the final monograph covering asthma and bronchodilator drugs.
FDA Final Rule For OTC Inhaler Labeling Requires Death Warning
FDA disagrees with industry comments regarding the health risks of using OTC asthma inhalers, rejecting suggested language for the final monograph covering asthma and bronchodilator drugs.